MENU

Hepatitis B Virus

HBV is the most common serious liver infection in the world. Worldwide, 2 billion people (1 out of 3 people) have been infected with hepatitis B and 400 million people have become chronically infected.

An estimated 1 million people worldwide die each year from hepatitis B virus infection and its complications; about 5,000 of those are in the U.S. The clinical manifestations are severe. Worldwide, chronic infection with hepatitis causes 80% of all hepatocellular carcinoma (HCC) and more than 500,000 people die each year from this lethal cancer. About 5% of the population are chronic carriers of HBV, and nearly 25% of all carriers develop serious liver diseases such as chronic hepatitis, cirrhosis, and HCC. With today’s medicines, the cure rate for chronic HBV infection is less than 10%. An RNAi therapeutic inhibiting all steps of the HBV life cycle and silencing tolerogenic viral antigens has the potential to achieve a “functional cure.”

show more

ALN-HBV for the Treatment of HBV Infection

We are developing ALN-HBV, an RNAi therapeutic targeting the HBV genome for the treatment of HBV infection. Our current ALN-HBV RNAi therapeutic represents a potentially powerful mechanism for inhibiting all steps of the HBV life cycle: replication, assembly, secretion of virus, and secretion of sub-viral antigens. ALN-HBV utilizes our ESC-GalNAc-conjugate delivery technology, enabling subcutaneous dosing with improved potency and durability, and a wide therapeutic index. We believe that ALN-HBV can become a “best-in-class” RNA therapeutic for the treatment of HBV infection.

Please read the latest press releases and data presentations for ALN-HBV here.

Less Content

Alnylam R&D Day 2014 Webcast and Presentations

Alnylam R&D Day 2014 Webcast and Presentations

On December 12, we hosted an R&D Day in New York City. Alnylam management and key opinion leaders discussed the latest progress as well as plans for the future development of our RNAi therapeutics pipeline. At this event, we announced our pipeline growth strategy for development and commercialization of RNAi therapeutics across three Strategic Therapeutic Areas (STArs): Genetic Medicines, Cardio-metabolic Disease, and Hepatic Infectious Disease.



Read More

New Programs Added to Infectious Disease Pipeline: ALN-HDV and ALN-PDL

New Programs Added to Infectious Disease Pipeline: ALN-HDV and ALN-PDL

We have expanded our infectious disease pipeline with two new RNAi therapeutic programs. First, we are advancing ALN-HDV, an RNAi therapeutic targeting the hepatitis delta viral (HDV) genome in development for the treatment of HDV infection. We are also advancing ALN-PDL, an RNAi therapeutic targeting hepatocyte-expressed programmed death ligand 1 (PD-L1) in development for the treatment of chronic liver infections.



Read More

Pre-Clinical Data with ALN-HBV for the Treatment of Hepatitis B Virus (HBV) Infection

We presented pre-clinical data with ALN-HBV, an RNAi therapeutic targeting the hepatitis B virus (HBV) genome for the treatment of HBV infection, at the TIDES 2014 meeting held May 12 – 15 in Providence, Rhode Island. Specifically, we reported significant, multi-log reductions in HBV surface antigen (HBsAg) and HBV viral titers, and showed evidence for an immune-mediated therapeutic effect in chronically infected chimpanzees.



Read More